Phase III
Mirikizumab met all primary endpoints against placebo and secondary endpoints against Cosentyx in the Phase III study, the Indianapolis-based pharma company announced.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 17, 2020.
AstraZeneca released positive data from the Phase III THALES trial of Brilinta (ticagrelor) used twice a day with an aspirin.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 15, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 13, 2020.
Although the trial failed to meet the primary endpoint of PFS, the data for overall survival as a co-primary endpoint is not yet mature. The company plans to continue the trial until the next planned analysis.
Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates.
Gilead Sciences reported additional data from its Phase III SIMPLE-Severe trial and a real-world retrospective group of patients with severe COVID-19.
Reltecimod is a synthetic peptide antagonist of both superantigen exotoxins and the CD28 T-cell costimulatory receptor.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 10, 2020.
PRESS RELEASES